Guangdong Marubi Biotechnology Co - Asset Resilience Ratio
Guangdong Marubi Biotechnology Co (603983) has an Asset Resilience Ratio of 7.59% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Guangdong Marubi Biotechnology Co current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Guangdong Marubi Biotechnology Co's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Guangdong Marubi Biotechnology Co total assets.
Liquid Assets Composition Over Time
This chart breaks down Guangdong Marubi Biotechnology Co's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Guangdong Marubi Biotechnology Co (603983) financial obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥355.94 Million | 7.59% |
| Total Liquid Assets | CN¥355.94 Million | 7.59% |
Asset Resilience Insights
- Limited Liquidity: Guangdong Marubi Biotechnology Co maintains only 7.59% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Guangdong Marubi Biotechnology Co Industry Peers by Asset Resilience Ratio
Compare Guangdong Marubi Biotechnology Co's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Natura &Co Holding S.A.
SA:NTCO3 |
Household & Personal Products | 2.89% |
|
Hangzhou Haoyue Personal Care Co Ltd
SHG:605009 |
Household & Personal Products | 8.39% |
|
PT Estee Gold Feet Tbk
JK:EURO |
Household & Personal Products | 26.52% |
|
Kolmar Holding
KO:024720 |
Household & Personal Products | 4.87% |
|
Able C&C
KO:078520 |
Household & Personal Products | 4.40% |
|
Englewood Lab Inc
KQ:950140 |
Household & Personal Products | 4.76% |
|
NFC Corporation
KQ:265740 |
Household & Personal Products | 8.12% |
|
Chungdamglobal Co. Ltd.
KQ:362320 |
Household & Personal Products | 16.00% |
Annual Asset Resilience Ratio for Guangdong Marubi Biotechnology Co (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Guangdong Marubi Biotechnology Co.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 8.42% | CN¥388.66 Million ≈ $56.87 Million |
CN¥4.61 Billion ≈ $675.09 Million |
+0.61pp |
| 2024-12-31 | 7.82% | CN¥395.70 Million ≈ $57.90 Million |
CN¥5.06 Billion ≈ $740.81 Million |
-15.71pp |
| 2023-12-31 | 23.52% | CN¥1.05 Billion ≈ $153.30 Million |
CN¥4.45 Billion ≈ $651.72 Million |
+12.82pp |
| 2022-12-31 | 10.70% | CN¥437.78 Million ≈ $64.06 Million |
CN¥4.09 Billion ≈ $598.67 Million |
-8.92pp |
| 2021-12-31 | 19.62% | CN¥738.09 Million ≈ $108.01 Million |
CN¥3.76 Billion ≈ $550.45 Million |
-2.00pp |
| 2020-12-31 | 21.62% | CN¥820.58 Million ≈ $120.08 Million |
CN¥3.80 Billion ≈ $555.34 Million |
-1.55pp |
| 2019-12-31 | 23.17% | CN¥796.14 Million ≈ $116.50 Million |
CN¥3.44 Billion ≈ $502.84 Million |
-- |
About Guangdong Marubi Biotechnology Co
Guangdong Marubi Biotechnology Co., Ltd. engages in the research and development, design, production, sale, and service of various cosmetics in China. The company offers eye care, skincare, cleansing, and beauty and other products. It sells its products under the Marubi, Lianhuo, Chunji, and Passional Lover brands. The company was founded in 2002 and is based in Guangzhou, China.